Speaker Profile
M.D., Ph.D., VP, Head of Discovery Biology and Early Clinical Development, Octant Bio
Biography
Matthew Albert is currently at Octant Bio, where he focuses on integrating translational medicine and innovative approaches to drug discovery and development. His work centers on harnessing advanced biomarker strategies, human genetics and functional genomics-driven insights to address rare diseases, with a commitment to making personalized medicine a reality. At Octant, Matthew collaborates across scientific disciplines, aiming to transform therapeutic approaches by combining small molecule corrector therapies with cutting-edge platform technologies. He leverages his extensive experience in human genetics and translational research to guide teams in developing next-generation therapies. Matthew's vision is anchored in the belief that accelerated innovation and personalized solutions are key to addressing unmet medical needs.
Talk
Unlocking Human Genetics for Precision Clinical Trials
At Octant Bio, we leverage deep mutational scans and genetic data to develop targeted small molecule therapies. By defining mechanistic insight into response to corrector therapy, we optimize strategies that advance precision medicine for genetic disorders. Our lead program focuses on Rhodopsin-associated Retinitis Pigmentosa (RHO-adRP), providing hope for approximately 50% of patients with amenable mutations.
Large-scale Data Solutions Showcase:
Octant Bio
Octant Bio is a biotechnology company using cutting-edge technologies to develop precision medicines. By combining synthetic biology, data-driven insights, and nano-scale high-throughput chemical screens, Octant is transforming drug discovery with the aim to improve patient outcomes across multiple therapeutic areas.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
